source
- Merck CEO warns Congress that restricting US-China biotech deals could cost America its biotech leadershipMerck CEO Rob Davis told Congress and the Trump administration that limiting or cutting off US-China dealmaking would jeopardize US biotech leadership. He emphasized that collaboration with Chines…
- Scancell to merge into Neuphoria and seek $89 million equity as AstraZeneca's breast cancer drug gains EU approvalScancell announced it will merge into Neuphoria Therapeutics, taking over Neuphoria's Nasdaq listing ($NEUP) and planning to change the ticker to SCLT. The combined entity aims to raise up to $89 m…